Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy

被引:111
作者
Hovind, P
Tarnow, L
Oestergaard, PB
Parving, HH
机构
[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[2] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
关键词
vascular endothelial growth factor; diabetic nephropathy; progression promoters; retinopathy;
D O I
10.1046/j.1523-1755.2000.07504.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Growth factors have been suggested to play a role in the development and progression of diabetic nephropathy. Vascular endothelial growth factor (VEGF) is a potent cytokine family that induces angiogenesis and markedly increases endothelial permeability. The aim of the present study was to investigate plasma levels of VEGF in a large cohort of type 1 diabetic patients with diabetic nephropathy and in longstanding type 1 diabetic patients with persistent normoalbuminuria, and to evaluate VEGF as a predictor of nephropathy progression. Methods. We measured VEGF with an enzyme-linked immunosorbent assay (ELISA) technique in 199 type 1 diabetic patients with diabetic nephropathy (122 males, age 41 +/- 10 years, diabetes duration 28 +/- 8 years), glomerular filtration rate (GFR) (median [range]) 75 [10-143] mL/min/1.73 m(2), and in 188 long-standing type 1 diabetic patients with persistent normoalbuminuria (115 males, age 43 +/- 10 years, diabetes duration 27 +/- 9 years). One hundred fifty-five of the proteinuric patients were followed for at least 3 years after baseline examination with yearly GFR measurements. Results. Plasma levels of VEGF were significantly increased in patients with nephropathy as compared to the normoalbuminuric group; (median [range]): 45.7 [22.0-410] versus 27.1 [22.0-355] ng/L, respectively, P < 0.001. This difference was ascribed to elevated VEGF levels in nephropathic men: 51.8 [22.0-410] versus 22.0 [22.0-308] ng/L, P < 0.001. No differences were found between women with and without nephropathy: 37.8 [22.0-325] versus 36.6 [22.0-335] ng/L, NS. In proteinuric patients with GFR above and below the median value, there was no difference in the level of VEGF, NS. Plasma VEGF was below the detection limit (22.0 ng/L) in 60 patients with nephropathy and 93 patients with normoalbuminuria, P < 0.001. The mean rate of GFR decline was 3.5 (SE: 0.4) mL/min/year, and the following baseline variables acted as predictors of progression: albuminuria, mean arterial blood pressure and male gender. Hemoglobin Al, and plasma VEGF did not act as predictors. No significant differences between patients with and without proliferative retinopathy were detected. Conclusions. Our data suggest that VEGF is elevated early in the course of diabetic nephropathy in men with type 1 diabetes mellitus. Baseline albuminuria, arterial blood pressure and male gender was predictors of diabetic nephropathy progression, while plasma VEGF and Hemoglobin A(1c) did not contribute. The importance of VEGF in the initiation of diabetic nephropathy remains to be established.
引用
收藏
页码:S56 / S61
页数:6
相关论文
共 34 条
[1]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[2]   Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins [J].
Anthony, FW ;
Evans, PW ;
Wheeler, T ;
Wood, PJ .
ANNALS OF CLINICAL BIOCHEMISTRY, 1997, 34 :276-280
[3]  
Aziz MYA, 1997, NEPHROL DIAL TRANSPL, V12, P1538
[4]   Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy [J].
Breyer, JA ;
Bain, RP ;
Evans, JK ;
Nahman, NS ;
Lewis, EJ ;
Cooper, M ;
McGill, J ;
Berl, T ;
Rohde, R ;
Hunsicker, LG ;
Lachin, J ;
Greenhouse, SW ;
Verme, DA ;
Turlington, TR ;
Burrows, PK ;
Wish, J ;
Sheehan, J ;
Pohl, M ;
Berl, T ;
Santiago, G ;
Hunsicker, L ;
Kern, EFO ;
Lemann, J ;
Blementhal, S ;
Bresnahan, BS ;
Hebert, L ;
Goldfarb, S ;
Kobrin, S ;
Rodby, R ;
Levey, A ;
McLaughlin, M ;
Williams, M ;
McGill, J ;
Whittler, F ;
Rutecki, G ;
Cattran, D ;
Lietz, S ;
Valaitis, D ;
Hano, J ;
Maxwell, D ;
Porush, J ;
Spitalewitz, S ;
Shapiro, K ;
Adler, S ;
Tolchin, N ;
Hoy, W ;
Bernstein, R ;
Svetkey, L ;
Sharon, Z ;
Rausenbaum, B .
KIDNEY INTERNATIONAL, 1996, 50 (05) :1651-1658
[5]   SELECTION OF ROUTINE METHOD FOR DETERMINATION OF GLOMERULAR-FILTRATION RATE IN ADULT PATIENTS [J].
BROCHNERMORTENSEN, J ;
RODBRO, P .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1976, 36 (01) :35-43
[6]   Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy [J].
Burgos, R ;
Simo, R ;
Audi, L ;
Mateo, C ;
Mesa, J ;
GarciaRamirez, M ;
Carrascosa, A .
DIABETOLOGIA, 1997, 40 (09) :1107-1109
[7]   High Levels of Biologically Active Vascular Endothelial Growth Factor (VEGF) are Produced by the Baculovirus Expression System [J].
Cohen, Tzafra ;
Gitay-Goren, Hela ;
Neufeld, Gem ;
Levi, Ben-Zion .
GROWTH FACTORS, 1992, 7 (02) :131-138
[8]   ALBUMINURIA REFLECTS WIDESPREAD VASCULAR DAMAGE - THE STENO HYPOTHESIS [J].
DECKERT, T ;
FELDTRASMUSSEN, B ;
BORCHJOHNSEN, K ;
JENSEN, T ;
KOFOEDENEVOLDSEN, A .
DIABETOLOGIA, 1989, 32 (04) :219-226
[9]   Maternal serum vascular endothelial growth factor during early pregnancy [J].
Evans, P ;
Wheeler, T ;
Anthony, F ;
Osmond, C .
CLINICAL SCIENCE, 1997, 92 (06) :567-571
[10]   ENZYME-IMMUNOASSAY - AN IMPROVED DETERMINATION OF URINARY ALBUMIN IN DIABETICS WITH INCIPIENT NEPHROPATHY [J].
FELDTRASMUSSEN, B ;
DINESEN, B ;
DECKERT, M .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1985, 45 (06) :539-544